Enrique Espinosa-Arranz - Publications

Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: February 02, 2026

Protein content of extracellular vesicles from patients with advanced melanoma changes upon progression to anti-PD1 therapy.

Journal: Scientific reports

Published: October 09, 2025

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 12, 2025

Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 02, 2024

SEOM-GEM clinical guidelines for cutaneous melanoma (2023).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 22, 2024

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs.

Journal: Cancer metastasis reviews

Published: August 20, 2023

Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: July 17, 2023

MiRNAs in renal cell carcinoma.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 03, 2022

Cardiac monitoring during trastuzumab therapy in metastatic breast cancer: early incidence of cardiac dysfunction.

Journal: Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

Published: December 08, 2021

Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Journal: European journal of hospital pharmacy : science and practice

Published: March 16, 2021

Melanoma proteomics suggests functional differences related to mutational status.

Journal: Scientific reports

Published: February 12, 2018

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

Journal: Medicine

Published: February 01, 2018